Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

Roller-coaster healthcare stock Hims & Hers Health ( HIMS -1.34%), whose stock got devastated last week by worries that it ...

Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...

Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...

Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operation | Hims & Hers ...

Hims & Hers Health's revenue grew 69% YoY, boosting its outlook. See why HIMS stock’s growth potential and high implied ...

Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...